Author:
Belada David,Prochazka Vit,Janikova Andrea,Campr Vit,Blahovcova Petra,Pytlik Robert,Sykorova Alice,Klener Pavel,Benesova Katerina,Pirnos Jan,Duras Juraj,Mocikova Heidi,Trneny Marek
Funder
Internal Grant Agency of the Czech Ministry of Health
Subject
Cancer Research,Oncology,Hematology
Reference26 articles.
1. Follicular lymphoma: 2018 update on diagnosis and management;Freedman;Am. J. Hematol.,2018
2. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma;Marcus;J. Clin. Oncol.,2008
3. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
4. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial;Salles;Lancet,2011
5. Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years;Salles;Blood,2017
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献